Black checkmark with a sparkle and a curved line underneath on a white background.
Company

BioAtla, Inc.

Ticker
BCAB
Sector
Industry
Report date
November 16, 2026
Valye AI Score

93

Very high visibility
Recent developments
Recent developments summary

Recent news includes BioAtla securing $9.2 million for clinical program advancements and multiple sector-wide biotech developments. No direct recent news headlines specifically about BioAtla's operational changes or financial results were identified in the latest period.

Recent developments:
  • BioAtla secured $9.2 million to advance its clinical programs as reported in April 2026 [N14].
Overview

BioAtla, Inc. is a biotechnology company focused on developing novel therapeutics. Founded in 2007, the company has a leadership team and board with extensive experience in biopharmaceutical research, development, and commercialization. BioAtla has no reported revenue as of the latest available data and is currently operating at a net loss. The company is advancing clinical trials and has secured funding to support its clinical programs. Recent SEC filings include an amended 10-K and a 10-Q with updated financial and governance information. The company completed a 50-for-1 share consolidation in April 2026.

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. BioAtla, Inc. is a biotechnology company with no reported revenue as of September 30, 2023, and a net loss of $7.897 million for the quarter ended September 30, 2026. The company reported limited liquidity with cash and equivalents of $576,000 and a current ratio of 0.05 as of September 30, 2026. The board comprises experienced biopharma professionals, and the company is advancing clinical programs with recent financing secured for development activities.

Scenarios for BCAB

Bull case model:

BioAtla's strong intellectual property foundation and experienced leadership team provide a solid basis for advancing its clinical pipeline. The company has secured additional funding to support clinical program advancements, which may facilitate progress through clinical trial phases. Its presentations at major oncology conferences indicate active engagement with the scientific community and potential for future partnerships or collaborations.

Bear case model:

BioAtla currently reports no revenue and operates at a net loss with limited liquidity, as indicated by a low current ratio and cash reserves. The company's financial position may constrain its ability to sustain operations without additional financing. Clinical development risks, including trial outcomes and regulatory hurdles, present significant challenges. The company's dependence on successful clinical advancement and capital raises introduces execution risk.

Moat:

BioAtla's moat is based on its proprietary biotechnology platform and extensive intellectual property portfolio, including over 500 issued patents credited to its CEO and co-founder. The company's leadership and board bring significant expertise in drug development and commercialization, supporting its ability to advance clinical programs. However, as a clinical-stage biotech company with no revenue, its competitive position depends heavily on successful clinical development and regulatory approvals.

Risks overview
Risks summary
BioAtla's biggest risk is its limited liquidity combined with the inherent uncertainties of clinical-stage biotechnology development, which may impact its operational sustainability and ability to advance its pipeline.
Risks details:

• Liquidity Risk: As of September 30, 2026, BioAtla had limited cash and equivalents ($576,000) and a current ratio of 0.05, indicating potential challenges in meeting short-term obligations without additional financing.
• Clinical Development Risk: BioAtla's business depends on successful advancement of its clinical programs, which face inherent risks including trial failures, regulatory delays, and uncertain outcomes.
• No Revenue Generation: The company has reported no revenue as of the latest available period, relying on financing and capital markets to fund operations and development activities.

FINAL FORECAST FOR BCAB

Final take one line
BioAtla, Inc. is a clinical-stage biotechnology company with detailed SEC disclosures and active clinical development but faces liquidity constraints and operational risks.
Final take 12 to 24 month view

Business trends: Advancement of clinical programs with secured funding and active engagement in oncology research.
Execution milestones: Progression through clinical trial phases and presentations at major scientific conferences.
Key risks: Limited liquidity, reliance on successful clinical development, and absence of revenue generation.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

93
LLM visibility overview
LLM Visibility known facts
  • BioAtla, Inc. is a biotechnology company focused on developing therapeutics, with a history dating back to its founding in 2007.
  • The company completed a 50-for-1 share consolidation effective April 6, 2026, with retroactive adjustments to share and per share amounts in filings.
  • BioAtla's leadership includes co-founder and CEO Jay M. Short, Ph.D., with extensive biotech industry experience and over 500 issued patents.
  • The board includes experienced directors with backgrounds in biopharma commercialization, clinical development, and scientific research, including Sylvia McBrinn, Mary Ann Gray, Susan Moran, and Lawrence Steinman.
  • The company had no revenue as of the latest available period ending September 30, 2023.
  • For the quarter ended September 30, 2026, BioAtla reported a net loss of $7.897 million and basic and diluted EPS of -$4.74 per share.
  • As of September 30, 2026, BioAtla had cash and cash equivalents of $576,000 and current assets of $946,000, with current liabilities of $20.692 million, resulting in a current ratio of 0.05 and a cash ratio of 0.03, indicating liquidity constraints.
  • BioAtla secured $9.2 million for clinical program advancements as reported in April 2026.
  • Recent news coverage includes multiple biotech sector developments and BioAtla-specific clinical progress and financing announcements.
  • The company is actively advancing clinical programs, including Phase 1 and Phase 2 trials, with presentations at major oncology conferences.
  • BioAtla's filings include an amended 10-K filed April 29, 2026, and a 10-Q filed November 16, 2026, providing updated financial and governance disclosures.
Sources
Sources - Context summary

Generated 2026-11-16

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-04-29 | 10-K/A
  • S2 | 2026-11-16 | 10-Q
Sources - News headlines
  • N1 | 2026-11-16 | www.nasdaq.com | Hogs Post Gains Across the Board on Friday | https://www.nasdaq.com/articles/hogs-post-gains-across-board-friday
  • N2 | 2026-11-16 | www.nasdaq.com | Wheat Posts Friday Gains | https://www.nasdaq.com/articles/wheat-posts-friday-gains-0
  • N3 | 2026-11-16 | www.nasdaq.com | Cattle Rounding Out the Week with Gains | https://www.nasdaq.com/articles/cattle-rounding-out-week-gains-0
  • N4 | 2026-11-16 | www.nasdaq.com | Soybeans Post Friday Gains Following Export Announcements | https://www.nasdaq.com/articles/soybeans-post-friday-gains-following-export-announcements
  • N5 | 2026-11-16 | www.nasdaq.com | Johnson & Johnson To Acquire Ollin Biosciences In $2.2 Bln Deal | https://www.nasdaq.com/articles/johnson-johnson-acquire-ollin-biosciences-22-bln-deal
  • N6 | 2026-11-16 | www.nasdaq.com | MapLight Moves Toward Phase 3 Schizophrenia Trial; VISTA Study Enrollment Continues | https://www.nasdaq.com/articles/maplight-moves-toward-phase-3-schizophrenia-trial-vista-study-enrollment-continues
  • N7 | 2026-11-16 | www.nasdaq.com | Cosan S.A. Reports Compass IPO, Raízen Restructuring, and Asset Sales in September 30, 2026 Interim Report | https://www.nasdaq.com/articles/cosan-sa-reports-compass-ipo-raizen-restructuring-and-asset-sales-september-30-2026
  • N8 | 2026-11-16 | www.nasdaq.com | Ecopetrol S.A. Announces Closure of SIC Investigation Initiated in 2024 | https://www.nasdaq.com/articles/ecopetrol-sa-announces-closure-sic-investigation-initiated-2024
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine